Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126)

Journal of Affective Disorders

Volumn 109, Issue 3, 2008, Pages 251-263

  Vieta, Eduard ^a,b   Suppes, Trisha ^c   Eggens, Ivan ^d   Persson, Inger ^d   Paulsson, Björn ^d   Brecher, Martin ^e  

^a UNIVERSITY OF BARCELONA   (Spain)

^b MCLEAN HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d ASTRAZENECA R AND D   (Sweden)

^e ASTRAZENECA   (United Kingdom)

Author keywords

Bipolar disorder; Divalproex; Lithium; Maintenance; Placebo; Quetiapine

Indexed keywords

GLUCOSE; LITHIUM; PLACEBO; QUETIAPINE; VALPROATE SEMISODIUM;

ADULT; ARTICLE; BIPOLAR I DISORDER; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIABETES MELLITUS; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPERINSULINEMIA; INCREASED APPETITE; INSULIN DEPENDENT DIABETES MELLITUS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MANIA; METABOLIC PARAMETERS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYDIPSIA; POLYURIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RHINOPHARYNGITIS; RISK REDUCTION; SEDATION; SIDE EFFECT; SOMNOLENCE; THIRST; TREMOR; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DEMOGRAPHY; DIBENZOTHIAZEPINES; DISORDERS OF EXCESSIVE SOMNOLENCE; FEMALE; HEADACHE; HUMANS; INTERNATIONAL COOPERATION; LITHIUM CARBONATE; MALE; NASOPHARYNGITIS; SEVERITY OF ILLNESS INDEX; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME; VALPROIC ACID; YOUNG ADULT;

EID: 45949104092     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jad.2008.06.001     Document Type: Article

References (40)

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 29 suppl 1 (2006) S43-S48
2. Barnes T.R. A rating scale for drug-induced akathisia. Br. J. Psychiatry 154 (1989) 672-676
3. Bowden C.L., Calabrese J.R., McElroy S.L., Gyulai L., Wassef A., Petty F., Pope Jr. H.G., Chou J.C., Keck Jr. P.E., Rhodes L.J., Swann A.Z., Hirschfeld R.M., Wozniak P.J., and Divalproex Maintenance Study Group. A randomised, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch. Gen. Psychiatry 57 (2000) 481-489
4. Bowden C.L., Calabrese J.R., Sachs G., Yatham L.N., Asghar S.A., Hompland M., Montgomery P., Earl N., Smoot T.M., DeVeaugh-Geiss J., and Lamictal 606 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch. Gen. Psychiatry 60 (2003) 392-400
5. Calabrese J.R., Bowden C.L., Sachs G., Yatham L.N., Behnke K., Mehtonen O.P., Montgomery P., Ascher J., Paska W., Earl N., DeVeaugh-Geiss J., and Lamictal 605 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J. Clin. Psychiatry 64 (2003) 1013-1024
6. Calabrese J.R., Keck Jr. P.E., Macfadden W., Minkwitz M., Ketter T.A., Weisler R.H., Cutler A.J., McCoy R., Wilson E., Mullen J., and for the BOLDER Study Group. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I and II depression. Am. J. Psychiatry 162 (2005) 1351-1360
7. Chengappa K.R., and Williams P. Barriers to the effective management of bipolar disorder: a survey of psychiatrists based in the UK and USA. Bipolar Disord. 7 suppl 1 (2005) 38-42
8. Colom, F., Vieta, E., Sanchez-Moreno, J., Goikolea, J.M., Popova, E., Bonnin, C.M., Scott, J., in press. Psychoeducation for bipolar II disorder: an exploratory, 5-year outcome subanalysis. J. Affect. Disord. [Electronic publication ahead of print].
9. Dupuy H.J. In: Wenger N.K., Mattson M.E., Furberg C.D., and Elinson J. (Eds). The Psychological General Well-being (PGWB) Index, in Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies (1984), Le Jacq Publishing Inc, New York 170-183
10. Fountoulakis K.N., Vieta E., Sanchez-Moreno J., Kaprinis S.G., Goikolea J.M., and Kaprinis G.S. Treatment guidelines for bipolar disorder: a critical review. J. Affect. Disord. 86 (2005) 1-10
11. Grunze H., Kasper S., Goodwin G., Bowden C., Moller H.J., and WFSBP Task Force on Treatment Guidelines for Bipolar Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, Part III: maintenance treatment. World J. Biol. Psychiatry 5 (2004) 120-135
12. In: Guy W. (Ed). ECDEU Assessment Manual for Psychopharmacology. Revised Edition (1976), US Department of Health, Education and Welfare, Washington, DC
13. Gyulai L., Bowden C.L., McElroy S.L., Calabrese J.R., Petty F., Swann A.C., Chou J.C., Wassef A., Risch C.S., Hirschfeld R.M., Nemeroff C.B., Keck Jr. P.E., Evans D.L., and Wozniak P.J. Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology 28 (2003) 1374-1382
14. Hardoy M.C., Garofalo A., Mellino G., Tuligi F., Cadeddu M., and Carta M.G. Quetiapine as add-on treatment for bipolar I disorder: efficacy in preventing relapse of depressive episodes. Clin. Pract. Epidemol. Ment. Health 3 (2007) 17
15. Kay S.R., Fiszbein A., and Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 13 (1987) 261-276
16. Keck Jr. P.E., Calabrese J.R., McIntyre R.S., McQuade R.D., Carson W.H., Eudicone J.M., Carlson B.X., Marcus R.N., Sanchez R., and Aripiprazole Study Group. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J. Clin. Psychiatry 68 (2007) 1480-1491
17. Ketter T.A., Houston J.P., Adams D.H., Risser R.C., Meyers A.L., Williamson D.J., and Tohen M. Differential efficacy of olanzapine and lithium in preventing manic or mixed recurrence in patients with bipolar I disorder based on number of previous manic or mixed episodes. J. Clin. Psychiatry 67 (2006) 95-101
18. Montgomery S.A., and Åsberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 134 (1979) 382-389
19. Potkin S.G., Thyrum P.T., Bera R., Carreon D., Alva G., Kalali A.H., and Yeh C. Open-label study of the effect of combination quetiapine/lithium therapy on lithium pharmacokinetics and tolerability. Clin Ther. 24 (2002) 1809-1823
20. Sheehan D.V. The Anxiety Disease (1983), NY, Scribner's, New York
21. Simpson G.N., and Angus J.W.S. A rating scale for extrapyramidal side effects. Acta. Psychiatr. Scand. 212 suppl 44 (1970) 11-19
22. Spearing M.K., Post R.M., Leverich G.S., Brandt D., and Nolen W. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res. 73 (1997) 159-171
23. Suppes T., Dennehy E.B., Hirschfeld R.M., Altshuler L.L., Bowden C.L., Calabrese J.R., Crismon M.L., Ketter T.A., Sachs G.S., and Swann A.C. Texas Consensus Conference Panel on medication treatment of bipolar disorder: the Texas implementation of medication algorithms: update to the algorithms for the treatment of bipolar disorder. J. Clin. Psychiatry 66 (2005) 870-886
24. Suppes T., Liu S., Brecher M., Paulsson B., and on behalf of the Trial 127 Investigators. Maintenance treatment in bipolar I disorder with quetiapine with lithium or divalproex: a placebo-controlled, randomized multicenter trial (trial D1447C00127). [Abstract]. Bipolar Disord. 10 suppl 1 (2008) 40
25. Thase M.E., Macfadden W., Weisler R.H., Chang W., Paulsson B., Khan A., Calabrese J.R., and for the BOLDER II Study Group. Efficacy of quetiapine monotherapy in bipolar I and II depression. J. Clin. Psychopharmacology 26 (2006) 600-609
26. Tohen M., Calabrese J.R., Sachs G.S., Banov M.D., Detke H.C., Risser R., Baker R.W., Chou J.C., and Bowden C.L. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am. J. Psychiatry 163 (2006) 247-256
27. Tohen M., Chengappa K.N., Suppes T., Baker R.W., Zarate C.A., Bowden C.L., Sachs G.S., Kupfer D.J., Ghaemi S.N., Feldman P.D., Risser R.C., Evans A.R., and Calabrese J.R. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br. J. Psychiatry 184 (2004) 337-345
28. Tohen M., Greil W., Calabrese J.R., Sachs G.S., Yatham L.N., Oerlinghausen B.M., Koukopoulos A., Cassano G.B., Grunze H., Licht R.W., Dell'Osso L., Evans A.R., Risser R., Baker R.W., Crane H., Dossenbach M.R., and Bowden C.L. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am. J. Psychiatry 162 (2005) 1281-1290
29. Tondo L., Baldessarini R.J., Hennen J., and Floris G. Lithium maintenance treatment of depression and mania in bipolar I and bipolar II disorders. Am. J. Psychiatry 155 (1998) 638-645
30. Vieta E. Mood stabilization in the treatment of bipolar disorder: focus on quetiapine. Hum. Psychopharmacol. 20 (2005) 225-236
31. Vieta E., Panicali F., Goetz I., Reed C., Comes M., and Tohen M. EMBLEM Advisory Board. Olanzapine monotherapy and olanzapine combination therapy in the treatment of mania: 12-week results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) observational study. J. Affect. Disord. 106 (2008) 63-72
32. Vieta E., Parramon G., Padrell R., Nieto E., Martinez-Aran A., Corbella B., Colom F., Reinares M., Goikolea J.M., and Torrent C. Quetiapine in the treatment of rapid cycling bipolar disorder. Bipolar Disord. 4 (2002) 335-340
33. Vieta E., and Suppes T. Bipolar II disorder: arguments for and against a distinct diagnostic entity. Bipolar Disord. 10 (2008) 163-178
34. Winter H.R., DeVane C.L., Figueroa C., Ennis D.J., Hamer-Maansson J.E., Davis P.C., and Smith M.A. Open-label steady-state pharmacokinetic drug interaction study on co-administered quetiapine fumarate and divalproex sodium in patients with schizophrenia, schizoaffective disorder, or bipolar disorder. Hum Psychopharmacol. 22 (2007) 469-476
35. Weisler R.H., Dunn J., and English P. Ziprasidone in adjunctive treatment of acute bipolar mania: a randomized, double-blind placebo-controlled trial. Eur. Neuropsychopharmacol. 13 suppl 4 (2003) S344
36. Yatham L.N., Grossman F., Augustyns I., Vieta E., and Rayindren A. Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial. Br. J. Psychiatry 182 (2003) 141-147
37. Yatham L.N., Kennedy S.H., O, ' Donovan C., Parikh S.V., MacQueen G., McIntyre R.S., Sharma V., Beaulieu S., Guidelines Group, and CANMAT. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord. 8 (2006) 721-739
38. Yatham L.N., Vieta E., Young A.H., Möller H.J., Paulsson B., and Vågero M. A double-blind, randomized, placebo-controlled trial of quetiapine as add-on treatment to lithium or divalproex for the treatment of bipolar mania. Int. Clin. Psychopharmacol. 22 (2007) 212-220
39. Young A.H. Treatment of bipolar disorder with antipsychotic medication: issues shared with schizophrenia. J. Clin. Psychiatry 68 suppl 6 (2007) 24-25
40. Young R.C., Biggs J.T., Ziegler V.E., and Meyer D.A. A rating scale for mania: reliability, validity and sensitivity. Br. J. Psychiatry 133 (1978) 429-435